|
May 15
|
Novavax Soars on Sanofi Deal: A Smart Buy or Post-Hype Correction?
|
|
May 15
|
Novavax Stock Just Tripled. Is It Too Late to Buy?
|
|
May 14
|
Sanofi to make €1bn biomanufacturing investment in France
|
|
May 14
|
Does Soaring Novavax Stock Have Enough Fuel to Climb Higher?
|
|
May 14
|
Trending tickers: Anglo American, GameStop, Vodafone, Greggs and Novavax
|
|
May 14
|
Fulcrum Therapeutics Inc (FULC) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
|
|
May 14
|
Exploring Three Dividend Stocks On Euronext Paris
|
|
May 13
|
Barrow, Hanley, Mewhinney & Strauss Bolsters Portfolio with Strategic Additions in Q1 2024
|
|
May 13
|
Novavax (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal
|
|
May 13
|
Meme Mania is Back: Buy these 3 Stocks
|
|
May 13
|
Sanofi strikes $1bn deal with Fulcrum for muscular dystrophy drug
|
|
May 13
|
Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag
|
|
May 13
|
Fulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ...
|
|
May 13
|
Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug
|
|
May 13
|
France bags $16 billion investment boost from Microsoft, Pfizer and others as Macron goes on FDI charm offensive
|
|
May 13
|
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
|
|
May 13
|
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
|
|
May 13
|
Novavax Inc (NVAX) (Q1 2024) Earnings Call Transcript Highlights: Strategic Partnerships and ...
|
|
May 13
|
Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty
|
|
May 13
|
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
|